{"id":4509,"date":"2010-11-23T01:21:38","date_gmt":"2010-11-23T05:21:38","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=4509"},"modified":"2010-11-23T01:21:38","modified_gmt":"2010-11-23T05:21:38","slug":"industry-on-parade-once-again","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2010\/11\/23\/industry-on-parade-once-again\/","title":{"rendered":"industry on parade once again…"},"content":{"rendered":"\n
I thought I was done with the Dr. Anil Potti story, but there’s one more piece – unfortunately all too familiar. Potti is a paid speaker for Eli Lilly and GSK [Glaxo-Smith-Klein]. Lilly makes one of the drugs being studied. In addition, Potti and Duke University are involved with CancerGuide, a company that was formed to perform the tests Potti was developing. Like with other medical scandals reported here – pharma, Universities, and Private labs are again "linked" to unethical behavior. It’s like a broken record…<\/div>\n
\n
Health care companies cut ties with Potti<\/a>
The Chronicle [Duke]<\/strong>
By Zachary Tracer
September 13, 2010<\/div>\n

Two health care companies have cut ties with a Duke cancer researcher whose research methods and credentials have been called into question. Eli Lilly and Company and CancerGuide Diagnostics ended their relationships with Dr. Anil Potti, an associate professor of medicine, over allegations that Potti falsified portions of his resume and committed research misconduct, company officials recently told The Chronicle.<\/sup><\/p>\n

The companies cut their ties with Potti in July after The Cancer Letter revealed evidence that Potti fabricated several awards on his resume, drawing new scrutiny to the cancer researcher’s science, which had been questioned for months. Duke also placed Potti on paid administrative leave in July, when the University began investigations into his credentials and research. “Based on the recent events, we terminated the relationship with Dr. Potti,” CancerGuide Diagnostics Chief Executive Officer Dr. Myla Lai-Goldman told The Chronicle. “Certainly, we’re disappointed”…<\/sup><\/p>\n

“While Duke was the basis for some of our early research, it’s not the foundation of CancerGuide’s future,” Lai-Goldman said. “The foundation of CancerGuide’s future is going to come from our own work, our own research, our own development.” The University also had an ownership stake in CancerGuide, but it has been working to divest its stake since the allegations against Potti emerged in July, said Dr. Michael Cuffe, vice president for medical affairs. Lai-Goldman declined to comment on Duke’s divestment from the company.<\/sup><\/p>\n

At Eli Lilly, a Fortune 500 pharmaceutical company, Potti served as a consultant and speaker, Carla Cox, a company spokesperson, wrote in an e-mail. Cox said Potti had been a member of the company’s thoracic speaker faculty since 2006 and had also participated in scientific advisory board meetings. Eli Lilly paid Potti $15,000 in 2010 to speak to other doctors, according to a disclosure document on the company’s website. Cox said Potti lectured to oncologists about one of Eli Lilly’s chemotherapy drugs…<\/sup><\/p>\n

Potti was also a consultant for GlaxoSmithKline, one of the largest pharmaceutical companies in the world. The company paid him $6,000 to participate in a clinical oncology advisory board meeting in 2009, Melinda Stubbee, a company spokesperson, wrote in an e-mail. But Stubbee said the company has no ongoing association with Potti…<\/sup><\/div>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"

I thought I was done with the Dr. Anil Potti story, but there’s one more piece – unfortunately all too familiar. Potti is a paid speaker for Eli Lilly and GSK [Glaxo-Smith-Klein]. Lilly makes one of the drugs being studied. In addition, Potti and Duke University are involved with CancerGuide, a company that was formed […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4509","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/4509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=4509"}],"version-history":[{"count":1,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/4509\/revisions"}],"predecessor-version":[{"id":7581,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/4509\/revisions\/7581"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=4509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=4509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=4509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}